Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi (SNY) has agreed to acquire Blueprint Medicines (BPMC) for $9.1 billion in cash, plus a contingent value right potentially adding another $400 million, to bolster its rare disease and immunology portfolios. The acquisition brings Sanofi Ayvakit/Ayvakyt, a treatment for advanced systemic mastocytosis which generated $479 million in revenue in 2024 and grew over 60% year-over-year in Q1 2025, as well as elenestinib and BLU-808. Sanofi expects the deal to close in Q3 2025, be immediately accretive to gross margin, and accretive to business operating income and EPS after 2026; separately, Sanofi also exercised its option to exclusively license Nurix Therapeutics' STAT6 program.

Analysis

Sanofi SA is strategically expanding its rare disease and immunology portfolios through the definitive agreement to acquire Blueprint Medicines Corporation for approximately $9.1 billion in cash, with an additional potential $400 million via contingent value rights (CVRs) linked to BLU-808 milestones, bringing the total potential equity value to $9.5 billion. This acquisition grants Sanofi ownership of Ayvakit/Ayvakyt, an approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM) that generated $479 million in net revenues in 2024 and demonstrated robust growth with nearly $150 million in Q1 2025, representing a year-over-year increase exceeding 60%. The deal also includes promising pipeline assets such as elenestinib for SM and BLU-808, a wild-type KIT inhibitor. Sanofi anticipates the transaction, expected to close in Q3 2025, will be immediately accretive to its gross margin and accretive to business operating income and EPS post-2026, without significantly impacting its 2025 financial guidance. CEO Paul Hudson highlighted that this complements recent early-stage acquisitions and that Sanofi retains substantial capacity for further M&A. Concurrently, Sanofi exercised its option to exclusively license Nurix Therapeutics' STAT6 program, including the oral STAT6 degrader NX-3911, further underscoring its commitment to strengthening its immunology franchise, particularly in type 2 inflammation-driven diseases.

Key Decisions for Investors

• Sanofi investors should view this acquisition as a strategic enhancement to its immunology and rare disease pipeline, with positive long-term accretion expected after 2026, and monitor the successful integration of Blueprint's assets and Sanofi's future M&A activities given its stated capacity.
• Blueprint Medicines shareholders are set to receive a significant cash premium at $129.00 per share, plus potential upside from CVRs linked to BLU-808's development, making the offer attractive.
• Investors should note the continued M&A appetite in the biotech sector, particularly for companies with approved, high-growth assets in specialized therapeutic areas like rare diseases and immunology, potentially signaling valuation uplifts for comparable entities.
• The licensing deal with Nurix Therapeutics provides positive validation for NRIX's STAT6 program and could be a precursor to deeper value creation for Nurix shareholders as the program advances under Sanofi's development.